Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Debt: 2020-2024

Historic Non-Current Debt for ImmunityBio (IBRX) over the last 4 years, with Dec 2024 value amounting to $284.4 million.

  • ImmunityBio's Non-Current Debt rose 15.53% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 15.53%. This contributed to the annual value of $284.4 million for FY2024, which is 83.00% up from last year.
  • Per ImmunityBio's latest filing, its Non-Current Debt stood at $284.4 million for FY2024, which was up 83.00% from $155.4 million recorded in FY2023.
  • ImmunityBio's 5-year Non-Current Debt high stood at $306.3 million for FY2021, and its period low was $155.4 million during FY2023.
  • For the 2-year period, ImmunityBio's Non-Current Debt averaged around $219.9 million, with its median value being $219.9 million (2023).
  • Data for ImmunityBio's Non-Current Debt shows a peak YoY surged of 83.00% (in 2024) over the last 5 years.
  • ImmunityBio's Non-Current Debt (Yearly) stood at $254.4 million in 2020, then increased by 20.44% to $306.3 million in 2021, then reached $155.4 million in 2023, then surged by 83.00% to $284.4 million in 2024.